KAMADA: FDA APPROVES SAN ANTONIO PLASMA COLLECTION CENTER

TL;DR

**Kamada just got FDA approval for its new plasma center, boosting its supply chain.**

AI Summary

Kamada Ltd. announced on March 26, 2026, that the U.S. Food and Drug Administration (FDA) has approved its new plasma collection center located in San Antonio, Texas. This approval is significant because it allows Kamada to expand its plasma sourcing capabilities, which are crucial for producing its life-saving plasma-derived protein therapeutics. For investors, this means a potentially more robust and diversified supply chain, reducing reliance on third-party plasma and potentially improving manufacturing efficiency and profitability, which could positively impact the stock price.

Why It Matters

This approval strengthens Kamada's control over its raw material supply, which is vital for its pharmaceutical production and could lead to improved operational efficiency and profitability.

Risk Assessment

Risk Level: low — The FDA approval of a new facility generally de-risks a company's operations by securing critical supply infrastructure.

Analyst Insight

A smart investor would view this as a positive operational development, potentially indicating improved future margins and supply stability, and might consider this a good time to review Kamada's long-term growth prospects.

Key Players & Entities

• Kamada Ltd. (company) — the filer and company receiving FDA approval
• U.S. Food and Drug Administration (FDA) (company) — the regulatory body granting approval
• San Antonio, Texas (location) — site of the newly approved plasma collection center
• March 26, 2026 (date) — date of the FDA approval and filing

Forward-Looking Statements

• Kamada's plasma supply chain will become more resilient and cost-effective. (Kamada Ltd.) — medium confidence, target: 2027-03-26
• The company may see an increase in its manufacturing capacity for plasma-derived products. (Kamada Ltd.) — medium confidence, target: 2027-03-26

FAQ

Filing Documents

• ea0283431-6k_kamada.htm (6-K) — 11KB
• ea028343101ex99-1.htm (EX-99.1) — 13KB
• 0001213900-26-034342.txt ( ) — 25KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2026 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720 , 333-207933 , 333-215983 , 333-222891 , 333-233267 and 333-265866 . The following exhibit is attached: 99.1 Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 26, 2026 KAMADA LTD. By: /s/ Nir Livneh Nir Livneh Vice President General Counsel and Corporate Secretary 2 EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas 3

View Full Filing

View this 6-K filing on SEC EDGAR